Scholarlink

<p>Metabolically associated fatty liver disease (MASLD) is highly prevalent among individuals with obesity and type 2 diabetes. Glucagon-like peptide-1 receptor agonists (GLP1-RA) and glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide (GLP1-RA/GIP) dual agonists have demonstrated favorable effects on liver health. Liver steatosis and stiffness can be noninvasively assessed using transient elastography with Fibroscan<sup>®</sup>. However, evidence regarding the impact of incretin therapy on these elastographic outcomes remains inconsistent across available studies. Indeed, we performed a systematic review and meta-analysis of randomized-controlled trials and case–control studies, which aimed to investigate the effect of GLP1-RA or GLP1-RA/GIP on liver stiffness and steatosis evaluated with Fibroscan<sup>®</sup> (PROSPERO registration number CRD420251162316). We searched PubMed, Web of Science, and Scopus for English-language studies till March 2025. Methodological quality of the studies was assessed by the Newcastle–Ottawa Scale or Jadad score. In the presence of heterogeneity, standardized (Std) mean differences with 95% confidence intervals (CIs) were combined using a random effect model. Funnel plot and trim-and-fill analysis were used to assess publication bias. Five studies were included in the analysis, accounting for 9 trials. A total of 554 patients and 270 controls were enrolled. The analysis revealed an improvement for both liver stiffness [std. mean difference = –&#xa0;0.3, 95%CI –&#xa0;0.5 to –&#xa0;0.1, <i>p</i> = 0.02] and liver steatosis [std. mean difference = –&#xa0;0.4, 95%CI –&#xa0;0.7 to –&#xa0;0.1, <i>p</i> = 0.03] at the end of the trial. Our findings showed that treatment with GLP1-RA and GLP1-RA/GIP in people with MASLD improves liver stiffness and steatosis evaluated through Fibroscan<sup>®</sup>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide on liver stiffness and steatosis evaluated through Fibroscan®: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2026年5月15日

查看全文
  • Antonella Berardicurti,
  • Settimio D’Andrea,
  • Francesco Cipollone,
  • Onorina Berardicurti,
  • Cosima Schiavone,
  • Andrea Boccatonda

摘要

Metabolically associated fatty liver disease (MASLD) is highly prevalent among individuals with obesity and type 2 diabetes. Glucagon-like peptide-1 receptor agonists (GLP1-RA) and glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide (GLP1-RA/GIP) dual agonists have demonstrated favorable effects on liver health. Liver steatosis and stiffness can be noninvasively assessed using transient elastography with Fibroscan®. However, evidence regarding the impact of incretin therapy on these elastographic outcomes remains inconsistent across available studies. Indeed, we performed a systematic review and meta-analysis of randomized-controlled trials and case–control studies, which aimed to investigate the effect of GLP1-RA or GLP1-RA/GIP on liver stiffness and steatosis evaluated with Fibroscan® (PROSPERO registration number CRD420251162316). We searched PubMed, Web of Science, and Scopus for English-language studies till March 2025. Methodological quality of the studies was assessed by the Newcastle–Ottawa Scale or Jadad score. In the presence of heterogeneity, standardized (Std) mean differences with 95% confidence intervals (CIs) were combined using a random effect model. Funnel plot and trim-and-fill analysis were used to assess publication bias. Five studies were included in the analysis, accounting for 9 trials. A total of 554 patients and 270 controls were enrolled. The analysis revealed an improvement for both liver stiffness [std. mean difference = – 0.3, 95%CI – 0.5 to – 0.1, p = 0.02] and liver steatosis [std. mean difference = – 0.4, 95%CI – 0.7 to – 0.1, p = 0.03] at the end of the trial. Our findings showed that treatment with GLP1-RA and GLP1-RA/GIP in people with MASLD improves liver stiffness and steatosis evaluated through Fibroscan®.